Literature review shows tirzepatide's effects on metabolic dysfunction-associated steatotic liver disease, indicating potential for better management.
Tirzepatide is a dual glucagon-like peptide-1/glucose-dependent insulinotropic peptide receptor agonist consisting one of the latest therapeutic options for diabetes and obesity. Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly frequent medical entity, possibly leading to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and cirrhosis. MASLD management is primarily based on weight loss and physical exercise. A number of randomized controlled trials (RCTs) with tirzepatide have been conducted in people with histologically-proven MASH and showed beneficial effects. Herein, we briefly review available evidence for the effects of tirzepatide on MASLD.
No takes yet. Share an insight, caveat, or question.
Blathra et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: